- 17Volume 4, 2021Sep 22, Issue 18Sep 09, Issue 17Aug 26, Issue 16Jul 20, Issue 14Jun 02, Issue 11May 19, Issue 10May 04, Issue 9Apr 20, Issue 8Apr 06, Issue 7Mar 23, Issue 6Mar 09, Issue 5Feb 23, Issue 4Feb 09, Issue 3Jan 26, Issue 2
- 16Volume 3, 2020Dec 15, Issue 25Dec 01, Issue 24Nov 17, Issue 23Oct 06, Issue 20Sep 08, Issue 18Aug 25, Issue 17Jul 14, Issue 14Jun 30, Issue 13Jun 16, Issue 12Jun 02, Issue 11May 19, Issue 10May 05, Issue 9Mar 10, Issue 5Feb 25, Issue 4Feb 04, Issue 3Jan 21, Issue 2Jan 07, Issue 01
- 15Volume 2, 2019Dec 17, Issue 22Nov 12, Issue 20Oct 28, Issue 19Oct 15, Issue 18Sep 03, Issue 15Aug 21, Issue 14Aug 05, Issue 13Jul 22, Issue 12Jul 08, Issue 11Jun 03, Issue 9May 13, Issue 8Apr 22, Issue 7Mar 11, Issue 4Feb 04, Issue 2Jan 21, Issue 1
- 14Volume 1, 2018Dec 21, Issue 12Dec 03, Issue 11Nov 19, Issue 10Nov 05, Issue 9Oct 22, Issue 8Oct 09, Issue 7Sep 24, Issue 6Sep 10, Issue 5Aug 15, Issue 4Jul 15, Issue 3Jul 01, Issue 1
Agenus on Twitter
Today, we took another step in advancing our immuno-oncology therapies to cancer patients. We announced that the first patient has been dosed with AGEN1777, our first-in-class #TIGIT bispecific licensed to @bmsnews, triggering a $20M milestone payment. investor.agenusbio.com/news-releases/…
WHO recommends broader use of the world’s first malaria vaccine, containing Agenus’ QS-21 Stimulon. Read today’s story from @BosBizJournal. @garo_armen bizjournals.com/boston/news/20…
Yesterday, @WHO rec. widespread use of the 1st malaria vaccine to young children in sub-Saharan Africa —what made the news more interesting was the fact that it was a 27-yr old biotech in Lexington that made the vaccine possible. @garo_armen @Agenus_Bio bit.ly/2YvXHgk Retweeted by Agenus Inc. ($AGEN)
Live from #BioFuture21, @jbuell01 discusses the future of cancer treatment and emerging areas of innovation in oncology
Targeting ILT-4 with $AGEN discovered antibody, MK-4830, may increase the anti-tumor activity of pembrolizumab even in tumors with low levels of T-cell inflammation. Publication in Clinical Cancer Research discusses potential of ILT-4 blockade to abrogate PD-1/PD-L1 resistance twitter.com/CCR_AACR/statu…
Antibody MK-4830 alone or in combination with #pembrolizumab shows antitumor activity and presents the potential for a new mechanism to treat anti–PD-1/PD-L1 resistance. https://t.co/wFb1Zq4Wb7.@lillian_siu pic.twitter.com/EHLBNvSGC2
— Clinical Cancer Research (@CCR_AACR) October 5, 2021
Tune in today, at 1:30pm EST, to hear @jbuell01 speak at the BioFuture 2021 panel, “Next Gen Oncology Therapeutics: Changing the Cancer Landscape.” biofuture.com/biofuture-regi…
Oh the talent density @Agenus_Bio and @MiNK_iNKT! twitter.com/jbuell01/statu…
Saturday I-O University w practice-changing giant @ODayMD; sharing lessons from curing melanomas to #conquer other cancers. The best part is… he’s on our team @Agenus_Bio! #cancer #Immunology pic.twitter.com/ulIBSgbkzm
— Jennifer Buell (@jbuell01) October 2, 2021
Agenus to Present AGEN1181 Clinical Data at SITC investor.agenusbio.com/news-releases/…
September is #GynecologicCancerAwarenessMonth and we at $AGEN are committed to fighting gynecologic cancers by advancing important therapeutic options for patients, spreading awareness, and encouraging education.
Bal/Zal Doubles Responses Compared to Currently Available Therapies at #ESMO21 Data demonstrate the power of our combo approach to improve patient outcomes and address difficult tumors, while remaining well-tolerated for patients. Today's Newsletter: agenusbio.com/newsletters/ag…
$AGEN featured in @endpts #ESMO21 highlights. Read here: endpts.com/the-best-of-th…
Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer onclive.com/view/balstilim… via @onclive Retweeted by Agenus Inc. ($AGEN)
Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer @myESMO #ESMO21 @OSUCCC_James #gyncsm onclive.com/view/balstilim… Retweeted by Agenus Inc. ($AGEN)
Results of a phase 2 study demonstrate that the anti-programmed death-1 (PD-1) antibody balstilimab from Agenus Inc. provides meaningful and durable clinical activity in patients with previously treated, recurrent/metastatic cervical cancer. bit.ly/3tHtaaw Retweeted by Agenus Inc. ($AGEN)
“Building Biotech: Masterclass w/ Jennifer Buell, Agenus COO” with @jbuell01 @Agenus_Bio, @Jack_O_Meara, @nabsicle, and DNA Tie Club. Sunday, Sep 19 at 10:00 AM PDT in @clubhouse! clubhouse.com/event/mgllK8Ap Retweeted by Agenus Inc. ($AGEN)
"Agenus congratulates @Ginkgo on their trading debut on @NYSE. We are excited to continue our collaboration with Ginkgo to revolutionize vaccines through our subsidiary @saponiQx" -@garo_armen twitter.com/Ginkgo/status/…
The future won’t be mined, extracted, wired or launched.
— Ginkgo Bioworks (@Ginkgo) September 17, 2021
It will be grown. pic.twitter.com/piGoTsqU6b
Bal/Zal combination data presented at #ESMO21 shows improved responses across histology subgroups, and anti-PD-1 alone. Further data to be presented on Sept. 19th. investor.agenusbio.com/news-releases/…
$AGEN combination of balstilimab plus zalifrelimab doubles responses in 2L cervical cancer in data to be presented at ESMO investor.agenusbio.com/index.php/news…
ICYMI: Follow the link to join, @jbuell01, this afternoon, at 4:20 EDT, for our presentation at the Baird 2021 Global Healthcare Conference. investor.agenusbio.com/events/event-d…
SaponiQx is proud to partner with @Ginkgo Bioworks to develop the next generation of saponin adjuvants. Pairing SaponiQx’s unique expertise in saponins and Gingko Bioworks’ Foundry technology will provide a platform for innovation! #Biotechnology #agenus investor.agenusbio.com/news-releases/… Retweeted by Agenus Inc. ($AGEN)